These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Performance of formulae based estimates of glomerular filtration rate for carboplatin dosing in stage 1 seminoma. Shepherd ST, Gillen G, Morrison P, Forte C, Macpherson IR, White JD, Mark PB. Eur J Cancer; 2014 Mar; 50(5):944-52. PubMed ID: 24445148 [Abstract] [Full Text] [Related]
6. Relevant risk of carboplatin underdosing in cancer patients with normal renal function using estimated GFR: lessons from a stage I seminoma cohort. Cathomas R, Klingbiel D, Geldart TR, Mead GM, Ellis S, Wheater M, Simmonds P, Nagaraj N, von Moos R, Fehr M. Ann Oncol; 2014 Aug; 25(8):1591-7. PubMed ID: 24669017 [Abstract] [Full Text] [Related]
7. Evaluation of glomerular filtration rate estimation by Cockcroft-Gault, Jelliffe, Wright and Modification of Diet in Renal Disease (MDRD) formulae in oncology patients. Ainsworth NL, Marshall A, Hatcher H, Whitehead L, Whitfield GA, Earl HM. Ann Oncol; 2012 Jul; 23(7):1845-53. PubMed ID: 22104575 [Abstract] [Full Text] [Related]
9. Carboplatin Dosing Accuracy by Estimation of Glomerular Filtration versus Creatinuria in Cancer Patients. Graciano Vera N, Pino Villarreal L, Ureña Vargas J. Chemotherapy; 2018 Jul; 63(3):137-142. PubMed ID: 29768260 [Abstract] [Full Text] [Related]
11. Analysis of carboplatin dosing in patients with a glomerular filtration rate greater than 125 mL/min: To cap or not to cap? A retrospective analysis and review. Morrow A, Garland C, Yang F, De Luna M, Herrington JD. J Oncol Pharm Pract; 2019 Oct; 25(7):1651-1657. PubMed ID: 30336729 [Abstract] [Full Text] [Related]
12. A comparison of measured and estimated glomerular filtration rate for carboplatin dose calculation in stage I testicular seminoma. Quinton A, Lewis P, Ali P, Morgan C, Bertelli G. Med Oncol; 2013 Oct; 30(3):661. PubMed ID: 23864250 [Abstract] [Full Text] [Related]
15. Carboplatin dosing based on measurement of renal function--experience at the Peter MacCallum Cancer Institute. Millward MJ, Webster LK, Toner GC, Bishop JF, Rischin D, Stokes KH, Johnston VK, Hicks R. Aust N Z J Med; 1996 Jun; 26(3):372-9. PubMed ID: 8811211 [Abstract] [Full Text] [Related]
17. Evaluation of creatinine-based formulas in dosing adjustment of cancer drugs other than carboplatin. Jennings S, de Lemos ML, Levin A, Murray N. J Oncol Pharm Pract; 2010 Jun; 16(2):113-9. PubMed ID: 19578094 [Abstract] [Full Text] [Related]
18. Chromium-51 ethylenediamine tetraacetic acid glomerular filtration rate: a better predictor than glomerular filtration rate calculated by the Cockcroft-Gault formula for renal involvement in systemic lupus erythematosus patients. Godfrey T, Cuadrado MJ, Fofi C, Abbs I, Khamashta MA, Nunan T, Hughes GR. Rheumatology (Oxford); 2001 Mar; 40(3):324-8. PubMed ID: 11285381 [Abstract] [Full Text] [Related]
19. Serum cystatin C-based equation compared to serum creatinine-based equations for estimation of glomerular filtration rate in patients with chronic kidney disease. Hojs R, Bevc S, Ekart R, Gorenjak M, Puklavec L. Clin Nephrol; 2008 Jul; 70(1):10-7. PubMed ID: 18793543 [Abstract] [Full Text] [Related]
20. Flat dosing of carboplatin is justified in adult patients with normal renal function. Ekhart C, de Jonge ME, Huitema AD, Schellens JH, Rodenhuis S, Beijnen JH. Clin Cancer Res; 2006 Nov 01; 12(21):6502-8. PubMed ID: 17085665 [Abstract] [Full Text] [Related] Page: [Next] [New Search]